Sarah Jane Jones

Dr. Sarah Jane Jones


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2007 in Experimental Cell Research
Verified
Journal Article
Closed access
SJSarah Jane Jones
Sarah Jane Jones
MFMargaret M. Florence
Margaret M. Florence
Ian EllisIan Ellis
Ian Ellis
KKKaterina Kankova
Katerina Kankova
SSSeth L. Schor
Seth L. Schor
ASAna M. Schor
Ana M. Schor

1 April 2000 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
VSValerie J Smith
Valerie J Smith
Jorge FernandesJorge Fernandes
Jorge Fernandes
SJSarah Jane Jones
Sarah Jane Jones
GKGraham D Kemp
Graham D Kemp
MTMary F Tatner
Mary F Tatner

15 December 2003
Verified
Journal Article
Closed access
SSSeth L Schor
Seth L Schor
Ian EllisIan Ellis
Ian Ellis
SJSarah Jane Jones
Sarah Jane Jones
RBRobin Baillie
Robin Baillie
KSKanjula Seneviratne
Kanjula Seneviratne
RKRichard A Kay
Richard A Kay

6 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AIAnem Iftikhar
Anem Iftikhar
Mohammad IslamMohammad Islam
Mohammad Islam
SSSimon Shepherd
Simon Shepherd
SJSarah Jane Jones
Sarah Jane Jones
Ian EllisIan Ellis
Ian Ellis
A single head and neck Cancer (HNC) is a globally growing challenge associated with significant morbidity and mortality. The diagnosis itself can affect the patients profoundly let alone the complex and disfiguring treatment. The highly important functions of structures of the head and neck such as mastication, speech, aesthetics, identity and social interactions make a cancer diagnosis in this region even more psychologically traumatic. The emotional distress engendered as a result of functional and social disruption is certain to negatively affect health-related quality of life (HRQoL). The key biological responses to stressful events are moderated through the combined action of two systems, the hypothalamus–pituitary–adrenal axis (HPA) which releases glucocorticoids and the sympathetic nervous system (SNS) which releases catecholamines. In acute stress, these hormones help the body to regain homeostasis; however, in chronic stress their increased levels and activation of their receptors may aid in the progression of cancer. Despite ample evidence on the existence of stress in patients diagnosed with HNC, studies looking at the effect of stress on the progression of disease are scarce, compared to other cancers. This review summarises the challenges associated with HNC that make it stressful and describes how stress signalling aids in the progression of cancer. Growing evidence on the relationship between stress and HNC makes it paramount to focus future research towards a better understanding of stress and its effect on head and neck cancer.

8 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Mohammad IslamMohammad Islam
Mohammad Islam
SJSarah Jane Jones
Sarah Jane Jones
Ian EllisIan Ellis
Ian Ellis
Metastasis is a critical step in the process of carcinogenesis and a vast majority of cancer-related mortalities result from metastatic disease that is resistant to current therapies. Cell migration and invasion are the first steps of the metastasis process, which mainly occurs by two important biological mechanisms, i.e., cytoskeletal remodelling and epithelial to mesenchymal transition (EMT). Akt (also known as protein kinase B) is a central signalling molecule of the PI3K-Akt signalling pathway. Aberrant activation of this pathway has been identified in a wide range of cancers. Several studies have revealed that Akt actively engages with the migratory process in motile cells, including metastatic cancer cells. The downstream signalling mechanism of Akt in cell migration depends upon the tumour type, sites, and intracellular localisation of activated Akt. In this review, we focus on the role of Akt in the regulation of two events that control cell migration and invasion in various cancers including head and neck squamous cell carcinoma (HNSCC) and the status of PI3K-Akt pathway inhibitors in clinical trials in metastatic cancers.

1 December 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
RKRichard A. Kay
Richard A. Kay
Ian EllisIan Ellis
Ian Ellis
SJSarah Jane Jones
Sarah Jane Jones
SPStépHane Perrier
StépHane Perrier
MFMargaret M. Florence
Margaret M. Florence
SSSeth L. Schor
Seth L. Schor
Migration stimulating factor (MSF) is a truncated oncofetal fibronectin isoform expressed by fetal and tumor-associated cells. MSF mRNA is distinguished from other fibronectin isoforms by its size (2.1 kb) and the inclusion of a specific intronic sequence at its 3′ end. Initial Northern blot analysis with a MSF-specific probe indicated the presence of this 2.1-kb transcript and an additional unexpected 5.9-kb RNA present in both MSF-secreting (fetal) and nonsecreting (adult) fibroblasts. Our investigations into the nature of these transcripts and their relationship to MSF protein secretion revealed that the 5.9-kb mRNA is a second MSF-encoding transcript. Both these mRNAs have identical coding sequence and differ only in the length of their intron-derived 3′-untranslated region (UTR). The 5.9-kb MSF mRNA is retained in the nucleus whereas the 2.1-kb mRNA is not. MSF-secreting fetal fibroblasts have significantly lower nuclear levels of the 5.9-kb mRNA and correspondingly higher cytoplasmic levels of the 2.1-kb transcript than their nonsecreting adult counterparts. Adult fibroblasts induced to secrete MSF by treatment with transforming growth factor-β1 displayed similar changes in their respective levels of MSF mRNA, but not those of a control gene. When cloned downstream of a reporter gene, only the longer 3′-UTR retained coding sequence within the nucleus. We conclude that expression of MSF protein is regulated by 3′-UTR truncation of the 5.9-kb nuclear-sequestered “precursor” MSF mRNA and nuclear export of mature 2.1-kb message. Inducible 3′-UTR processing represents a novel regulatory mechanism involved in cancer pathogenesis that may open new avenues for therapeutic gene delivery.